PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ)
$9.24 0.08 (0.8734%)
Analysed PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) News Sources
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
30-07-2026
yahoo.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05-08-2026
yahoo.com
Puma Biotechnology Reports Second Quarter 2026 Financial Results
06-08-2026
yahoo.com
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary
07-08-2026
moby.co
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
07-08-2026
yahoo.com
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
11-05-2026
yahoo.com
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
14-05-2026
yahoo.com
Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ...
07-08-2026
yahoo.com
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
12-08-2026
yahoo.com
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
14-08-2026
fool.com
What is the current price of PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ)?
The current price of PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) is $9.24.
PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) absolute price change since previous trading day?
The absolute price change of PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) since the previous trading day is $0.08.
PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) percentage price change since previous trading day?
The percentage price change of PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) since the previous trading day is 0.8734%.
What is the most recent average sentiment score for PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ)?
The most recent average sentiment score for PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ)?
The most recent sentiment for PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ) is .
SEC-8K** Filing Available For PUMA BIOTECHNOLOGY INC (PBYI:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.